Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The current study aims to explore the clinical effects and mechanistics of mono- and
combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on
renal physiology and biomarkers in metformin-treated T2DM patients.